Active — Not RecruitingEarly Phase 1

A Pilot Study on Reverse Aging (The REVERSE Study)

United States52 participantsStarted 2025-02-15

Plain-language summary

Aging can be defined as a time-dependent functional decline in physiological function, which may increase the vulnerability to diseases and eventually death. The question is whether aging is a normal process, or exists as an "uber-illness?" Work done by Dr Sinclair at Harvard suggests the latter. Dr. Sinclair feels people should be able to age-in-place, or even reverse age. Aging is arguably the single biggest risk factor for all acquired and chronic diseases. Delaying the aging rate by 7 years would cut the incidence of chronic disease in half! Up until know the effects of anti-aging would need longitudinal studies until death. Now, with the advent of a 3rd generation OMIC Age clock, there is a way to assess if an intervention is changing the rate of aging and other methylation patterns associated with aging.

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects will be healthy and of any sex, any ethnicity, and any age from 50 to 80 * "Healthy" subjects will be defined as a real-world cohort of individuals likely to utilize such an intervention * May be on other medications if they do not conflict with rapamycin. * All medical conditions need to be stable and well controlled. * Willing and able to provide informed consent Exclusion Criteria: * Severe illnesses, for which rapamycin may cause harm. This would not be limited to but include active neoplastic or auto-immune disease. If patients have a previous history of cancer or auto-immune disease, the risks and benefits and possible adverse reactions will be discussed at time of consent * History of organ transplant * Any unstable medical condition that would interfere with the study * Hepatic impairment. Note: Patients with elevated liver enzymes and low albumin, will be further screened for hepatic impairment. Elevated liver enzymes \< 2x upper limit of normal will not be considered hepatic impairment. * Renal impairment, indicated by a serum creatinine \> 1.4 mg/dL * Anemia indicated by a hemoglobin \< 12 g/dL * Platelets \< 80,000/cumm, * ANC \< 1,000 / cumm * Total WBC \< 3,000/cumm * Pregnancy or breastfeeding or woman of childbearing potential with inadequate contraception * Unstable mental illness * A condition where rapamycin may interfere deleteriously with a medication that is taken by a potential subject * Currently prescribed with high d…

What they're measuring

Change in Biological Age from Baseline to End of Study based on Tru Diagnostic Tru Age OMICm Age test results.

Timeframe: 24 weeks

Trial details

NCT IDNCT07354620

SponsorThe Christ Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-02